Pooled analysis of phase III with entacapone in Parkinson's disease
✍ Scribed by Kuoppamäki, M.; Vahteristo, M.; Ellmén, J.; Kieburtz, K.
- Book ID
- 126981119
- Publisher
- John Wiley and Sons
- Year
- 2014
- Tongue
- English
- Weight
- 318 KB
- Volume
- 130
- Category
- Article
- ISSN
- 0001-6314
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract We aimed to investigate whether treatment with levodopa/carbidopa/entacapone when compared with levodopa/carbidopa improves quality of life in Parkinson's disease (PD) patients with no or minimal, nondisabling motor fluctuations. This is a multicenter, randomized, double‐blind study. On
## Abstract Entacapone (EN) improves the efficacy of levodopa/dopadecarboxylase inhibitor (LD/DDI) formulations by inhibition of the enzyme catechol‐__O__‐methyltransferase (COMT). COMT inhibition also promotes the synthesis of basic LD metabolites, whereas DDI support the composition of acidic LD